The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
复制标题
卵巢癌免疫检查点阻断的预测和预后生物标志物的现状
DOI:
10.3389/fimmu.2022.1045957
复制
发表时间:
2022
影响因子:
7.3
通讯作者:
He, Xiujing
中科院分区:
文献类型:
--
作者:
Xu, Yufei;Zuo, Fengli;Wang, Huiling;Jing, Jing;He, Xiujing
Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian cancer (OC). However, only a subset of patients derive clinical benefit, and immune-related adverse events (irAEs) caused by ICB therapy can lead to permanent tissue damage and even fatal consequences. It is thus urgent to develop predictive biomarkers to optimize patient outcomes and minimize toxicity risk. Herein, we review current predictive and prognostic biomarkers for checkpoint immunotherapy in OC and highlight emerging biomarkers to guide treatment with ICB. The prevalent biomarkers, such as PD-L1 expression status, tumor-infiltrating lymphocytes, mutational burden, and immune gene signatures, are further discussed. We provide a state-of-the-art survey on prognostic and predictive biomarkers for checkpoint immunotherapy and offer valuable information for guiding precision immunotherapy
登录
查看更多内容
影响因子:
5.5
作者:
Li X;Liang W;Zhao H;Jin Z;Shi G;Xie W;Wang H;Wu X
通讯作者:
Wu X
影响因子:
3.7
作者:
通讯作者:
--
影响因子:
10.9
作者:
Gong J;Chehrazi-Raffle A;Reddi S;Salgia R
通讯作者:
Salgia R
影响因子:
3.6
作者:
Liu, Fangran;Liu, Jiao;Xu, Guoxiong
通讯作者:
Xu, Guoxiong
影响因子:
22.7
作者:
Bratman, Scott V.;Yang, S. Y. Cindy;Pugh, Trevor J.
通讯作者:
Pugh, Trevor J.